Glaxo withdraws Relenza prevention NDA

Glaxo (GLX; LSE:GLXO) withdrew its NDA for Relenza zanamivir, an inhaled neuraminidase inhibitor, to prevent influenza A and B infection in

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE